Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Takeda Initiates Voluntary Partial Recall for Azilva due to Incorrect Expiry Date on Packaging Carton
April 25, 2013
- GSK Files NDA for LAMA/LABA Combination Drug for COPD Treatment
April 24, 2013
- Shionogi Revises Profit Forecasts for FY2012
April 24, 2013
- AnGes MG’s CIN Therapeutic Vaccine Demonstrates Increased Efficacy in Combination with Kampo Medicine
April 24, 2013
- Merck Serono to Launch New Gonalef Pen Devices Starting in May
April 24, 2013
- Ibandronate Injection Non-Inferior to Risedronate: Chugai, Taisho
April 23, 2013
- Nichi-Iko to Launch Allegra AG in June, Says Identical with Original
April 23, 2013
- Daiichi Sankyo Launches Silodosin in China
April 23, 2013
- Ono Pharmaceutical Obtains Exclusive Rights for Once-Daily Wearing-Off Treatment
April 22, 2013
- Pfizer-Mylan Pair’s Japan Generic Share at 2.8%, Aspire for Bigger Slice of Market
April 22, 2013
- Taisho Files SGLT-2 Inhibitor Luseogliflozin, Submits RMP
April 22, 2013
- Merck Serono Obtains Marketing Rights for Cetrotide from Shionogi
April 22, 2013
- AnGes MG, Shionogi to Start PI Study for Nucleic Acid Drug for Atopic Dermatitis
April 19, 2013
- Daiichi Sankyo to Enter Branded Generics Business in Brazil with Launch of 2 Products
April 19, 2013
- Eli Lilly Japan Aims to Be a Top-10 Drug Maker in Japan by 2020, but Re-pricing and Generic Competition Could Pose Obstacles
April 19, 2013
- Tug-of-War over “Conflicts of Interest” (2): “Diovan Scandal” Brings Renewed Attention to COI
April 19, 2013
- Taisho, Nissui Launch Switch OTC Epadel; Prior Doctor Consultation Required for Patients
April 18, 2013
- Meiji Seika Pharma Licenses Schizophrenia Treatment from MSD, to Market It Independently
April 18, 2013
- Novo Nordisk Ups Efforts in Basal Insulin Market, Pits Tresiba against Lantus
April 18, 2013
- Pfizer’s Palbociclib Receives Breakthrough Therapy Designation from US FDA
April 18, 2013
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…